Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.34 |
| ▸ | KDM4A | O75164 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.34 |
| ▸ | TET3 | O43151 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10311696 | 0.78 | CYP2D6 (0.39) | CYP2D6CYP2C19CYP2C9KMT2AALDH1A1 | |
| SCHEMBL10072998 | 0.78 | CYP2D6 (0.39) | CYP2D6CYP2C19CYP2C9KMT2AALDH1A1 | |
| SCHEMBL10311725 | 0.78 | CYP2D6 (0.39) | CYP2D6CYP2C19CYP2C9KMT2AALDH1A1 | |
| SCHEMBL17680117 | 0.78 | CYP2D6 (0.39) | CYP2D6CYP2C19CYP2C9KMT2AALDH1A1 | |
| SCHEMBL13534167 | 0.78 | CYP2D6 (0.39) | CYP2D6CYP2C19CYP2C9KMT2AALDH1A1 | |
| SCHEMBL7082573 | 0.76 | OR51E2 (0.42) | CYP2D6CYP2C19OR51E2SMN1; SMN2TET2 | |
| SCHEMBL1769044 | 0.76 | GFPT1 (0.49) | — | |
| SCHEMBL1769047 | 0.76 | GFPT1 (0.49) | — | |
| SCHEMBL18125949 | 0.75 | CYP2D6 (0.52) | CYP2D6CYP2C19OR51E2TP53SMN1; SMN2 | |
| SCHEMBL3354440 | 0.75 | CYP2D6 (0.59) | CYP2D6CYP2C19CYP2C9KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977339-B2 | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20100311649-A1 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7795265-B2 | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090118300-A1 | Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118300-A1 | Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators | CCKAR, CCKBR, GPR119 | CYP2D6 2801/4885CYP2C19 1652/4885OR51E2 774/4885 |
| US-20100311649-A1 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | CCKAR, CCKBR, GPR119 | CYP2D6 2801/4885CYP2C19 1652/4885OR51E2 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.